"Multi-stakeholder approach" key to sustainable biosimilars market, says EGA
This article was originally published in Scrip
Among the numerous challenges facing the biosimilars market are winning the trust of all stakeholders in the biosimilars concept, tackling misinformation, and encouraging the implementation of policies that can ensure the sustainability of the market in the long run.
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.